Results 221 to 230 of about 34,140,631 (244)

Reasons for and Outcomes of Medicare Part D Appeals for Denied GLP‐1 Receptor Agonist Claims

Diabetes, Obesity and Metabolism, EarlyView.
Matthew J. Klebanoff, John C. Lin, Judith A. Long, Eric Bressman, Jalpa A. Doshi   +4 more
wiley   +1 more source

The Glucagon-like Peptide-1 Receptor Agonist Era and Its Influence on Body-Contouring Referrals After Weight Loss in Appalachia. [PDF]

Plast Reconstr Surg Glob Open
Rahimpour A, Stuart I, Hyde JH, Roberts-Moore K, Price KR, Keefer JD, Persily A, Bown P, Barry R.   +8 more
europepmc   +1 more source

Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis. [PDF]

Cancers (Basel)
Ailawadi S, Murphy JE, Storandt MH, Mahipal A.   +3 more
europepmc   +1 more source

Clinical outcomes of glucagon-like peptide-1 receptor agonist therapy in kidney transplant recipients: a systematic review and meta-analysis. [PDF]

Clin Kidney J
Kanbay M, Abdel-Rahman SM, Guldan M, Ozbek L, Genc NI, Ak AB, Covic A, Goren HK.   +7 more
europepmc   +1 more source

Comparison of Pediatric and Adult Glucagon-Like Peptide-1 Receptor Agonist Exposures Reported To United States Poison Centers, 2017-2024. [PDF]

J Med Toxicol
Senthilkumar A, Hays HL, Kistamgari S, Rine NI, Rhodes AL, Gaw CE, Smith GA.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Hope Rugo, Laura Huppert
exaly  

From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimer’s disease

Cell, 2021
Francesca Perini, Louis Dwomoh, Brian Hudson   +2 more
exaly  

Pharmacological Characterization of Veldoreotide as a Somatostatin Receptor 4 Agonist

Life, 2021
Thomas Günther, Stefan Schulz, Pooja Dasgupta   +2 more
exaly  

Recent Molecular Insights into Agonist-specific Binding to the Mu-Opioid Receptor

Frontiers in Molecular Biosciences, 2022
Mahmoud Al-Khrasani, Kornel Király, Ferenc Zádor   +2 more
exaly  

Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma

Journal of Ocular Pharmacology and Therapeutics, 2023
Makoto Aihara, Takashi Omoto, Hitomi Saito   +2 more
exaly